Vestnik Dermatologii i Venerologii · Published 2026-03-28 · DOI 10.25208/vdv16953
Psoriasis and psoriatic arthritis are characterized by a high prevalence, a chronic progressive course, the frequent presence of severe forms, comorbidities, and a significant decrease in patients’ quality of life, which justifies high demands on the efficacy and safety of therapy for these diseases. The article describes two clinical cases of the successful use of the interleukin 17 (IL-17) inhibitor netakimab in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. Netakimab was administered at a dose of 120 mg as subcutaneous injections once weekly on weeks 0, 1, and 2, followed by 120 mg once every 4 weeks. The treatment efficacy was assessed by clinical and laboratory examination using PASI, DAS28, and NAPSI scores. Netakimab treatment resulted in regression of subjective and objective skin symptoms and sustained clinical and laboratory remission of joint syndrome. Netakimab treatment was free of adverse events and significantly improved patients’ quality of life.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →